Skip to content
2000
image of Diagnosis and Management of Group 3 Pulmonary Hypertension in the UAE: Pulmonary Hypertension Associated with Chronic Lung Disease (PH-CLD)

Abstract

Chronic Lung Diseases (CLDs) constitute one of the most frequent causes of pulmonary hypertension (PH) and rank second after PH due to left heart disease. In PH-CLD, destruction of lung parenchyma is associated with decreased functional capacity, diminished quality of life, increased oxygen requirements, and a heightened risk of death.

As both pulmonary arterial hypertension (PAH) and PH due to lung disease are categorized as precapillary PH, it is essential to distinguish between the two conditions, particularly when the lung disease is present with the severe form of PH. If the diagnosis confirms a severe form of PH-CLD, then individualised care is essential in patients with severe lung disease and evidence of right-sided heart failure, particularly those with lower-limb oedema. Moreover, echocardiography (ECHO) and N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) evaluation are of high importance and must be ordered by the pulmonologist. Right Heart Catheterisation (RHC) is also essential for the determination of the extent and severity of pulmonary vascular involvement. The use of inhaled vasodilators, along with a referral for right heart catheterisation, should be considered at an earlier phase of interstitial lung disease. In addition to therapy, cardiopulmonary rehabilitation programmes have been found to improve six-minute walking tests (6MWT), oxygenation, and functional capacity.

This article discusses the screening of PH-CLD along with the treatment algorithm and suggests the promising role of vasodilators in PH-CLD.

This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/nemj/10.2174/0102506882333573241119082734
2024-12-16
2025-01-19
Loading full text...

Full text loading...

/deliver/fulltext/nemj/10.2174/0102506882333573241119082734/e02506882333573.html?itemId=/content/journals/nemj/10.2174/0102506882333573241119082734&mimeType=html&fmt=ahah

References

  1. Nathan S.D. Barbera J.A. Gaine S.P. Harari S. Martinez F.J. Olschewski H. Olsson K.M. Peacock A.J. Pepke-Zaba J. Provencher S. Weissmann N. Seeger W. Pulmonary hypertension in chronic lung disease and hypoxia. Eur. Respir. J. 2019 53 1 1801914 10.1183/13993003.01914‑2018 30545980
    [Google Scholar]
  2. Sakkijha H. Idrees M. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: Pulmonary hypertension due to lung diseases and/or hypoxia. Ann. Thorac. Med. 2014 9 5 Suppl. 1 56 10.4103/1817‑1737.134030 25076998
    [Google Scholar]
  3. Humbert M. Kovacs G. Hoeper M.M. Badagliacca R. Berger R.M.F. Brida M. Carlsen J. Coats A.J.S. Escribano-Subias P. Ferrari P. Ferreira D.S. Ghofrani H.A. Giannakoulas G. Kiely D.G. Mayer E. Meszaros G. Nagavci B. Olsson K.M. Pepke-Zaba J. Quint J.K. Rådegran G. Simonneau G. Sitbon O. Tonia T. Toshner M. Vachiery J.L. Vonk Noordegraaf A. Delcroix M. Rosenkranz S. Schwerzmann M. Dinh-Xuan A.T. Bush A. Abdelhamid M. Aboyans V. Arbustini E. Asteggiano R. Barberà J.A. Beghetti M. Čelutkienė J. Cikes M. Condliffe R. de Man F. Falk V. Fauchier L. Gaine S. Galié N. Gin-Sing W. Granton J. Grünig E. Hassoun P.M. Hellemons M. Jaarsma T. Kjellström B. Klok F.A. Konradi A. Koskinas K.C. Kotecha D. Lang I. Lewis B.S. Linhart A. Lip G.Y.H. Løchen M.L. Mathioudakis A.G. Mindham R. Moledina S. Naeije R. Nielsen J.C. Olschewski H. Opitz I. Petersen S.E. Prescott E. Rakisheva A. Reis A. Ristić A.D. Roche N. Rodrigues R. Selton-Suty C. Souza R. Swift A.J. Touyz R.M. Ulrich S. Wilkins M.R. Wort S.J. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 2022 43 38 3618 3731 10.1093/eurheartj/ehac237 36017548
    [Google Scholar]
  4. Andersen C. Mellemkjær S. Hilberg O. Bendstrup E. NT-proBNP <95 ng/l can exclude pulmonary hypertension on echocardiography at diagnostic workup in patients with interstitial lung disease. Eur. Clin. Respir. J. 2016 3 1 32027 10.3402/ecrj.v3.32027 27478030
    [Google Scholar]
  5. Nathan S.D. Progress in the treatment of pulmonary hypertension associated with interstitial lung disease. Am. J. Respir. Crit. Care Med. 2023 208 3 238 246 10.1164/rccm.202212‑2342CI 37159942
    [Google Scholar]
  6. Louvaris Z. Vogiatzis I. Physiological basis of cardiopulmonary rehabilitation in patients with lung or heart disease. Breathe (Sheff.) 2015 11 2 120 127 10.1183/20734735.021114 26306112
    [Google Scholar]
  7. Grünig E. Eichstaedt C. Barberà J.A. Benjamin N. Blanco I. Bossone E. Cittadini A. Coghlan G. Corris P. D’Alto M. D’Andrea A. Delcroix M. de Man F. Gaine S. Ghio S. Gibbs S. Gumbiene L. Howard L.S. Johnson M. Jurevičienė E. Kiely D.G. Kovacs G. MacKenzie A. Marra A.M. McCaffrey N. McCaughey P. Naeije R. Olschewski H. Pepke-Zaba J. Reis A. Santos M. Saxer S. Tulloh R.M. Ulrich S. Vonk Noordegraaf A. Peacock A.J. ERS statement on exercise training and rehabilitation in patients with severe chronic pulmonary hypertension. Eur. Respir. J. 2019 53 2 1800332 10.1183/13993003.00332‑2018 30578391
    [Google Scholar]
  8. Walsh S.L.F. Devaraj A. Enghelmayer J.I. Kishi K. Silva R.S. Patel N. Rossman M.D. Valenzuela C. Vancheri C. Role of imaging in progressive-fibrosing interstitial lung diseases. Eur. Respir. Rev. 2018 27 150 180073 10.1183/16000617.0073‑2018 30578332
    [Google Scholar]
  9. Mereles D. Ehlken N. Kreuscher S. Ghofrani S. Hoeper M.M. Halank M. Meyer F.J. Karger G. Buss J. Juenger J. Holzapfel N. Opitz C. Winkler J. Herth F.F.J. Wilkens H. Katus H.A. Olschewski H. Grünig E. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006 114 14 1482 1489 10.1161/CIRCULATIONAHA.106.618397 16982941
    [Google Scholar]
  10. Fox B.D. Kassirer M. Weiss I. Raviv Y. Peled N. Shitrit D. Kramer M.R. Ambulatory rehabilitation improves exercise capacity in patients with pulmonary hypertension. J. Card. Fail. 2011 17 3 196 200 10.1016/j.cardfail.2010.10.004 21362526
    [Google Scholar]
  11. Kabitz H.J. Bremer H.C. Schwoerer A. Sonntag F. Walterspacher S. Walker D.J. Ehlken N. Staehler G. Windisch W. Grünig E. The combination of exercise and respiratory training improves respiratory muscle function in pulmonary hypertension. Lung 2014 192 2 321 328 10.1007/s00408‑013‑9542‑9 24338088
    [Google Scholar]
  12. Shoemaker M.J. Wilt J.L. Dasgupta R. Oudiz R.J. Exercise training in patients with pulmonary arterial hypertension: A case report. Cardiopulm. Phys. Ther. J. 2009 20 4 12 18 10.1097/01823246‑200920040‑00003 20467524
    [Google Scholar]
  13. Talwar A. Sahni S. Verma S. Khan S.Z. Dhar S. Kohn N. Exercise tolerance improves after pulmonary rehabilitation in pulmonary hypertension patients. J. Exerc. Rehabil. 2017 13 2 214 217 10.12965/jer.1732872.436 28503536
    [Google Scholar]
/content/journals/nemj/10.2174/0102506882333573241119082734
Loading
/content/journals/nemj/10.2174/0102506882333573241119082734
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test